New Illinois Lawsuit Claims Actos Bladder Cancer

A new lawsuit alleging Actos side effects was filed in the Circuit Court of Cook County, Illinois on November 8, 2012. In his complaint, William Wagner names Takeda Pharmaceuticals, et al., and Eli Lilly and Company.

A resident of Ohio, Wagner started taking Actos on August 9, 2007. He was diagnosed with bladder cancer on March 4, 2009 and, according to his legal complaint, the permanent and severe injuries he has sustained occurred as a result of his use of the type II diabetes drug.

Plaintiff claims Actos is a dangerous product

The plaintiff alleges failure to warn, misrepresentation of product safety, continuing to manufacture a product that was known to be dangerous, and inadequate testing. This case is an individual lawsuit, but there is a class action lawsuit underway in Louisiana consisting of other plaintiffs who have filed suit alleging side effects from the medication, as well as a case consolidation located in California.

Through his Actos lawyer, Wagner states that he has suffered from emotional distress and economic losses due to his illness and that he would not have used Actos had he been aware of the dangers involved with it.

He alleges that as a direct result of their acts and omissions on the part of the manufacturer, he suffered from various problems.

Studies indicate a link between Actos and bladder cancer

Actos is prescribed to treat type II diabetes, which is the most common form of the condition. When the body doesn’t produce enough insulin or fails to properly utilize the insulin that it does produce, the person is diagnosed with type II diabetes. Actos is meant to improve the body’s production or make more efficient the use of insulin. Wagner, however, asserts that the drug is defective and that individuals who have used Actos for a continuous period stand an increased risk of bladder cancer.

In addition, Wagner claims that Takeda and the other defendants failed to disclose their knowledge of the link between the medication and bladder cancer to medical professionals and the general population.

Several studies are cited to bolster Wagner’s allegations including a two-years carcinogenicity study and the 2005 PROactive three-year study indicating a possible connection between the drug and the disease.

[SmartLink actoslawsuit]